World Glaucoma Congress 2019 » WGC-2019 Confirmed Faculty

Thursday 3.45 pm-4.45 pmRoom 219

C4
Blood flow measurements in glaucoma: Ready for Prime Time?

Chair(s): Leopold Schmetterer (Austria); Michael S. Kook (South Korea);

3.45-4.00
Invasive Angiography: New and Old
Osamah Saeedi (United States)
4.00-4.15
Application of OCT-A in glaucoma - Facts and artifacts
Christopher Leung (Hong Kong)
4.15-4.30
Systemic Assessment of Vascular Regulation
Konstantin Gugleta (Switzerland)
4.30-4.45
Treatment for Vascular Dysregulation
Gerhard GarhÃ¶fer (Austria)

Thursday 3.45 pm-4.45 pmRoom 210 & 211

C5
Angle Closure: Diagnosis and Treatment

Chair(s): Hon-Tym Wong (Singapore); Shan Lin (United States);

3.45-3.57
Definitions & prevelence of angle closure
Paul Foster (United Kingdom)
3.57-4.09
Diagnosis and charactarisation
Ronnie George (India)
4.09-4.21
Clear lens extraction (pros and cons)
Poemen Chan (Hong Kong)
4.21-4.33
Practical tips for clear lens extraction
Shenton Chew (New Zealand)
4.33-4.45
Secondary angle closure
Mohammad Pakravan (Iran)

Thursday 3.45 pm-4.45 pmRoom 216

C7
Glaucoma's top model

Chair(s): Francesca Cordeiro (United Kingdom); Hari Jayaram (United Kingdom);

3.45-3.57
Acute vs Chronic Models: pros and cons
Hari Jayaram (United Kingdom)
3.57-4.09
Microbead models of glaucoma: pros and cons
Derek Welsbie (United States)
4.09-4.21
The ocular explant mouse model of ocular hypertension : a study on RGCs and mitochondria in glaucoma
Harry Quigley (United States)
4.21-4.33
The monkey model for glaucoma
Anita Chan (Singapore)
4.33-4.45
DARC technique to monitor RGC apoptosis
Francesca Cordeiro (United Kingdom)

Thursday 3.45 pm-4.45 pmRoom 217

C10
Surviving as a clinician scientist: around the world

Chair(s): Leonard Levin (Canada); Harsha Rao (India);

3.45-3.57
Japan
Ryo Asaoka (Japan)
3.57-4.09
Mexico
Jibran Mohamed-Noriega (Mexico)
4.09-4.21
Singapore
Rachel Chong (Singapore)
4.21-4.33
Germany
Katharina Bell (Germany)
4.33-4.45
Canada
Leonard Levin (Canada)

Thursday 3.45 pm-4.45 pmRoom 220

C11
Fuelling the power house

Chair(s): Miriam Kolko (Denmark); Ian Trounce (Australia);

3.45-3.57
Mitochondrial Therapeutics for Optic Nerve Dysfunction
Ian Trounce (Australia)
3.57-4.09
A clinical approach to study the role of mitochondria in Human Glaucoma
David Garway-Heath (United Kingdom)
4.09-4.21
Mitochondria & Astrocytes in the Optic Nerve Head - Relevance to Human Glaucoma
Nicholas Marsh-Armstrong (United States)
4.21-4.33
Mitochondrial biomarkers in human glaucoma
Patrick Yu Wai Man (United Kingdom)
4.33-4.45
The Impact of Ageing upon the Optic Nerve Head
Bang Bui (Australia)

Thursday 3.45 pm-4.45 pmRoom 203 & 204

C13
Tube complications

Chair(s): Nick Strouthidis (United Kingdom); Paul Chew (Singapore);

3.45-3.57
Corneal decompensation
Sheng Lim (United Kingdom)
3.57-4.09
Erosions
Christiane Rolim de Moura (Brazil)
4.09-4.21
Hypertensive phase
Jeffrey Freedman (United States)
4.21-4.33
Hypotony
Da-Wen Lu (Taiwan)
4.33-4.45
Late failure
Leon Au (United Kingdom)

Thursday 3.45 pm-4.45 pmRoom 218

C19
When the going gets tough: Making it easier for your patient

Chair(s): Ivan Goldberg (Australia); Alan Robin (United States);

3.45-3.55
Maximizing adherence to minimize disease
Michael Boland (United States)
3.55-4.05
Apps & aids to assist the patient with severe glaucoma
Mona Kaleem (United States)
4.05-4.15
Optimizing the ocular surface for comfort and vision
Jod Mehta (Singapore)
4.15-4.25
Maximizing functionality and Minimizing disability in the advanced glaucoma patient
Michael Yapp (Australia)
4.25-4.35
Living with glaucoma: the patient's perspective
Christopher Grikscheit (Australia)
4.35-4.45
What do patient's want from glaucoma surgery?
Amanda Bicket (United States)

Thursday 3.45 pm-4.45 pmRoom 212 & 213

C20
Beyond IOP: Are there other modifiable risk factors in glaucoma?

Chair(s): Fotis Topouzis (Greece); Jonathan Crowston (Australia);

3.45-3.57
"Iatrogenic glaucoma": the story of blood pressure treatment
Fotis Topouzis (Greece)
3.57-4.09
Are other diseases playing a role in my patient's "glaucoma"?
Mitchell Lawlor (Australia)
4.09-4.21
Can dietary changes help prevent glaucoma progression?
Catherine Birt (Canada)
4.21-4.33
Can physical activity prevent glaucoma?
Vicki Chrysostomou (Australia)
4.33-4.45
Going beyond the eye: does visual perception help us understand brain function?
Allison McKendrick (Australia)

Thursday 5.00 pm-6.00 pmRoom 220

C3
Perfect your glaucoma clinical exam

Chair(s): Esther Hoffman (Germany); Mark Walland (Australia);

5.00-5.12
Perfecting the Angle Assessment
Hon-Tym Wong (Singapore)
5.12-5.24
Perfecting the Optic Nerve Assessment
Anton Hommer (Austria)
5.24-5.36
Perfecting Assessment of Pediatric Patients
Elena Bitrian (United States)
5.36-5.48
Systemic Considerations: Looking Beyond the Eye
Andrew White (Australia)
5.48-6.00
Tonometry Tips: Perfecting IOP Assessment
Carroll Webers (Netherlands)

Thursday 5.00 pm-6.00 pmRoom 203 & 204

C6
Managing the Glaucoma Suspect

Chair(s): Robert Fechtner (United States); Neeru Gupta (Canada);

5.00-5.15
Mimickers of Glaucomatous Optic Nerves
Bill Morgan (Australia)
5.15-5.30
Considerations for the Myopic Glaucoma Suspect
Lucy Shen (United States)
5.30-5.45
OCT is Best For Managing Glaucoma Suspects
Syril Dorairaj (United States)
5.45-6.00
Visual Fields are Best for Managing Glaucoma Suspects
Albert Khouri (United States)

Thursday 5.00 pm-6.00 pmRoom 210 & 211

C22
Genetics for the non-geneticist

Chair(s): Subhabrata Chakrabarti (India); John Fingert (United States);

5.00-5.10
How can you tell that genetics are involved in a disease and traits- Introduction to heritability
Alex Hewitt (Australia)
5.10-5.20
Importance of families/pedigrees in genetic studies
David Mackey (Australia)
5.20-5.30
Complex inheritance patterns
John Fingert (United States)
5.30-5.40
Labwork & genetics- what is involved
Monica Melo (Brazil)
5.40-5.50
What is a GWAS?
Ching-Yu Cheng (Singapore)
5.50-6.00
Why would you even bother mapping genes? Translation of GWAS results
Stuart MacGregor (Australia)

Thursday 5.00 pm-6.00 pmRoom 219

C24
Analyzing the evidence

Chair(s): Ravi Thomas (Australia); Alan Robin (United States);

5.00-5.15
Integrating glaucoma clinical trial data into clinical practice
Anne Louise Coleman (United States)
5.15-5.30
Understanding simple and complex statistics in research publications
Steven Mansberger (United States)
5.30-5.45
Meta-analyses: value, pitfalls, and guides to interpreting results
Paul Healey (Australia)
5.45-6.00
Reading about surgical outcomes - what should I be looking for?
Alan Robin (United States)

Friday 3.45 pm-4.45 pmRoom 216

C1
Lasers in glaucoma: Finding the right spot

Chair(s): Lisandro Sakata (Brazil); Tony Realini (United States);

3.45-3.55
Endocyclophotocoagulation
Carla Siegfried (United States)
3.55-4.05
External cyclophotocoagulation
Ying Han (United States)
4.05-4.15
Laser trabeculoplasty (how)
Nuno Lopes (Portugal)
4.15-4.25
Laser trabeculoplasty (when?)
Tony Realini (United States)
4.25-4.35
Micropulse
Ying Han (United States)
4.35-4.45
Laser iridoplasty
Tony Wells (Australia)

Friday 3.45 pm-4.45 pmRoom 210 & 211

C2
Artificial intelligence: The future of glaucoma?

Chair(s): Linda Zangwill (United States); Xiulan Zhang (China);

3.45-3.57
What is AI?
Linda Zangwill (United States)
3.57-4.09
Deep learning for identifying glaucoma related features in fundus images
Naama Hammel (United States)
4.09-4.21
Deep learning assessment of OCT images
Michael Girard (Singapore)
4.21-4.33
Machine learning for visual field interpretation
Osamah Saeedi (United States)
4.33-4.45
The role of AI in clinical practice
Xiulan Zhang (China)

Friday 3.45 pm-4.45 pmRoom 220

C8
Going with the flow? OCT-A and other emerging technologies in glaucoma management

Chair(s): Leopold Schmetterer (Austria); Kaweh Mansouri (Switzerland);

3.45-3.57
Doppler Techniques for Assessing Blood Flow
Leopold Schmetterer (Austria)
3.57-4.09
OCT-A of drainage blebs
Monisha Nongpiur (Singapore)
4.09-4.21
Ocular blood flow in human glaucoma
Joao Barbosa Breda (Portugal)
4.21-4.33
The role of OCT-A in clinical glaucoma
Grace Richter (United States)
4.33-4.45
Anterior segment angiography â past and future
Anne Brooks (Australia)

Friday 3.45 pm-4.45 pmPlenary 2

C16
The Many Faces of Dreaded Bleb Complications

Chair(s): Alain Bron (France); Jody Piltz Seymour (United States); Tetsuya Yamamoto (Japan);

3.45-3.57
The dysesthetic bleb
Ramanjit Sihota (India)
3.57-4.09
The encapsulated bleb
Eugenio A Maul (Chile)
4.09-4.21
The infected bleb
Fabian Lerner (Argentina)
4.21-4.33
The leaking bleb
Jody Piltz Seymour (United States)
4.33-4.45
The overfiltering bleb
Esther Hoffman (Germany)

Friday 3.45 pm-4.45 pmRoom 219

C18
Surgical approaches to secondary glaucoma

Chair(s): Makoto Aihara (Japan); Jamie Brandt (United States);

3.45-3.57
ICE Syndrome
Sirisha Senthil (India)
3.57-4.09
Neovascular glaucoma
Janet Serle (United States)
4.09-4.21
Silicone oil - associated glaucoma
Guy D'Mellow (Australia)
4.21-4.33
Sturge Weber
Jamie Brandt (United States)
4.33-4.45
Uveitic glaucoma
Viney Gupta (India)

Friday 3.45 pm-4.45 pmRoom 212 & 213

C18
Glaucoma and lens extraction: where are we?

Chair(s): Vital Costa (Brazil); Jian Ge (China);

3.45-3.55
Phaco considerations in the pseudo exfoliation eye
Arvind Haripriya (India)
3.55-4.05
Refractive and IOL issues in glaucoma patients
Michael Coote (Australia)
4.05-4.15
What did we learn from the EAGLE trial?
Paul Foster (United Kingdom)
4.15-4.25
What is the added value of MIGS to phacoemulsification
Nathan Kerr (Australia)
4.25-4.35
When is phaco alone the best procedure with open angles?
Delan Jinapriya (Canada)
4.35-4.45
When is phaco trab the best procedure with open angles?
Vital Costa (Brazil)

Friday 3.45 pm-4.45 pmRoom 217

C21
Integrating genetics into clinical practice

Chair(s): Robert Casson (Australia); Eranga Vithana (Singapore);

3.45-3.57
The future of genetics
Stuart MacGregor (Australia)
3.57-4.09
How do you find & motivate family members to seek care?
Annie Gibbins (Australia)
4.09-4.21
What genetics cause glaucoma & where can you get them tested?
Susie Williams (South Africa)
4.21-4.33
Considering age, type of glaucoma, and other factors to screen family members intelligently
Srinivasan Kavitha (India)
4.33-4.45
Practical tips about when and how to implement genetic screening in clinical practice
John Fingert (United States)

Friday 3.45 pm-4.45 pmRoom 218

C23
Convince your government and payors that what you do is useful & cost-effective

Chair(s): Jennifer Burr (United Kingdom); Peter Sumich (Australia); Anja Tuulonen (Finland);

3.45-3.57
Comanagement with optometry: lowering costs while preserving quality of care
Alan Robin (United States)
3.57-4.09
Comparing the effectiveness of treatment alternatives
Jennifer Burr (United Kingdom)
4.09-4.21
How do I measure the utility of my efforts?
4.21-4.33
My government doesn't pay for MIGS - what do I do?
Randy au Craven (United States)
4.33-4.45
Fostering sustainable glaucoma care
Anja Tuulonen (Finland)

Friday 5.00 pm-6.00 pmRoom 220

C9
Stretching the Cables: Biomechanics

Chair(s): Nick Strouthidis (United Kingdom); Jost Jonas (Germany);

5.00-5.12
Associations between Laminar Compliance and Visual Field Loss: Is Stiffer Better?
Michael Girard (Singapore)
5.12-5.24
The Translaminar Pressure Difference: Key to Glaucoma?
Jost Jonas (Germany)
5.24-5.36
Imaging and Biomechanics of the Laminar Microarchitecture: Whatâs Happening at the Beam and Axon Level?
Nick Strouthidis (United Kingdom)
5.36-5.48
IOP, CSFP, and OPP Dynamics: What are We Missing in the Clinic?
John Flanagan (United States)
5.48-6.00
IOP Dynamics and Visual Field Progression: Are IOP Spikes the Culprit?
Carlos Gustavo de Moraes (United States)

Friday 5.00 pm-6.00 pmRoom 210 & 211

C12
The brave new world in managing glaucoma

Chair(s): Murray Fingeret (United States); Sayoko Moroi (United States);

5.00-5.12
What should OCT be telling you about a patients glaucoma
Murray Fingeret (United States)
5.12-5.24
Glaucoma Biomarkers - hiding in the aqueous?
Carla Siegfried (United States)
5.24-5.36
Glaucoma Care Driven by Artificial Intelligence
Sameer Trikha (Singapore)
5.36-5.48
Drop-Free Glaucoma Treatment- The Patients' Dream Come True..
Ian Pitha (United States)
5.48-6.00
Stem Cell therapy for the Trabecular Meshwork
Yang Sun (United States)

Friday 5.00 pm-6.00 pmRoom 203 & 204

C14
Tackling challenging glaucoma: a case based approach

Chair(s): Franz Grehn (Germany); Remo Susanna Jr. (Brazil); Thasarat Vajaranant (United States);

5.00-5.12
Big eyes
Norman Aquino (Philippines)
5.12-5.24
Post corneal surgery
Thasarat Vajaranant (United States)
5.24-5.36
Post vitrectomy
Augusto Paranhos Jr (Brazil)
5.36-5.48
Small eyes
Jimmy Lai (Hong Kong)
5.48-6.00
Expulsive choroidal hemorrhage
Arvind Neelakantan (United States)

Friday 5.00 pm-6.00 pmRoom 219

C15
Tubes: varied techniques

Chair(s): Prin Rojanapongpun (Thailand); Mark Sherwood (United States); Luis AbegÃ£o Pinto (Portugal);

5.00-5.12
Choice of tube: valved or non-valved
Henny Beckers (Netherlands)
5.12-5.24
Cost effective options
Srinivasan Kavitha (India)
5.24-5.36
Tube location and sealing methods
Jaewan Choi (South Korea)
5.36-5.48
Methods of early IOP control: wicks, fenestrations, abterators and meds
Luis AbegÃ£o Pinto (Portugal)
5.48-6.00
To tunnel or not to tunnel
Jesus Jimenez Roman (Mexico)

WGC-2019 Confirmed Faculty

Thursday 3.45 pm-4.45 pmRoom 219

C4Blood flow measurements in glaucoma: Ready for Prime Time?

Thursday 3.45 pm-4.45 pmRoom 210 & 211

C5Angle Closure: Diagnosis and Treatment

Thursday 3.45 pm-4.45 pmRoom 216

C7Glaucoma's top model

Thursday 3.45 pm-4.45 pmRoom 217

C10Surviving as a clinician scientist: around the world

Thursday 3.45 pm-4.45 pmRoom 220

C11Fuelling the power house

Thursday 3.45 pm-4.45 pmRoom 203 & 204

C13Tube complications

Thursday 3.45 pm-4.45 pmRoom 218

C19When the going gets tough: Making it easier for your patient

Thursday 3.45 pm-4.45 pmRoom 212 & 213

C20Beyond IOP: Are there other modifiable risk factors in glaucoma?

Thursday 5.00 pm-6.00 pmRoom 220

C3Perfect your glaucoma clinical exam

Thursday 5.00 pm-6.00 pmRoom 203 & 204

C6Managing the Glaucoma Suspect